China Universal Asset Management Company’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.68M Sell
49,000
-4,135
-8% -$620K 0.46% 46
2026
Q1
$8.12M Buy
53,135
+17,135
+48% +$2.63M 0.61% 36
2025
Q4
$4.96M Buy
36,000
+16,000
+80% +$2.1M 0.38% 52
2025
Q3
$2.56M Buy
20,000
+5,000
+33% +$610K 0.21% 90
2025
Q2
$1.82M Buy
15,000
+3,780
+34% +$426K 0.17% 115
2025
Q1
$1.28M Hold
11,220
0.12% 156
2024
Q4
$1.09M Buy
+11,220
New +$1.2M 0.1% 151

Other funds holding NVS

China Universal Asset Management Company's NVS Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Novartis (NVS) stake by 7.8% in Q2 2026, selling an estimated $620K and leaving 49,000 shares worth $7.68M. The position accounts for 0.46% of the portfolio, ranked #46.

China Universal Asset Management Company first reported a position in NVS in Q4 2024 and has held it in 7 quarters since. The position peaked at $8.12M in Q1 2026. 652 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • China Universal Asset Management Company held 49,000 shares of Novartis worth $7.68M as of Q2 2026.
  • China Universal Asset Management Company sold 4,135 Novartis shares in Q2 2026, an estimated $620K.
  • Novartis made up 0.46% of China Universal Asset Management Company's portfolio in Q2 2026, its #46 holding.
  • China Universal Asset Management Company first reported a position in Novartis in Q4 2024 and has held it in 7 quarters since.
  • China Universal Asset Management Company's Novartis position peaked at $8.12M in Q1 2026.
  • 652 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.